The prevalence of healthcare-associated infections is currently a critical issue in the medical community, resulting in compromised patient healthcare and billions of dollars in corrective costs. Further complicating this issue is the emergence of multi-drug-resistant organisms.
Symbios has developed an advanced manufacturing platform, based on plasma chemistry, that is being applied to the synthesis of novel antimicrobial solutions in a collaborative effort with a bioscience partner. Lab testing of this approach has demonstrated excellent antimicrobial effects against a wide range of microbial contaminants and thus demonstrates great promise as an anti-infective healthcare product. The Symbios plasma technology using the newly designed Selective Plasma Oxidation Reactor™ (SPOR™) represents a significant advancement toward the production of anti-infective solutions due to its continuous flow configuration, low energy consumption, and faster reaction times.
Connect with us!
Want to hear more about Symbios Technologies and our advanced plasma platform?
Reach us at info@symbiostechnologies.com
or